AI-driven protein research and development platform company Tianhu Technology has completed hundreds of millions in Series A++ financing.

On July 13th, Shanghai Tianwu Technology Co., Ltd., an AI-driven protein research and development platform company, announced the completion of a multi-billion yuan A++ round of financing. This round of financing was led by Shanghai Guotou XianDao and Guotou Innovation, with Jujie Microfiber, Ningbo Yongyuan Xinglun Junjin Capital, Jingxin Xinyan, Futeng Capital, and Caixin Capital as co-investors. Existing shareholders Qiming Venture Partners, Yonghua Investment, Jinsha River Joint Capital Runpu Medical Fund, Bencao Capital, and Shanghai Technology Innovation Fund continue to invest. This round of financing will be mainly used for the iteration of artificial intelligence technology, including the continuous research and development and iterative upgrade of the company's core product, Matwing Venus, an intelligent body for protein research in the "dry-wet closed loop," and to accelerate the scale application of AI-driven protein design capabilities in the fields of circular economy, innovative drugs, health, medical consumables, and other areas, further promoting the industrialization of AI for Science achievements from the laboratory to the industry.